TELA Bio Past Earnings Performance
Past criteria checks 0/6
TELA Bio's earnings have been declining at an average annual rate of -10.1%, while the Medical Equipment industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 32.5% per year.
Key information
-10.1%
Earnings growth rate
78.5%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 32.5% |
| Return on equity | n/a |
| Net Margin | -60.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Even With A 27% Surge, Cautious Investors Are Not Rewarding TELA Bio, Inc.'s (NASDAQ:TELA) Performance Completely
Nov 09
Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 33%
Aug 19Does TELA Bio (NASDAQ:TELA) Have A Healthy Balance Sheet?
Jul 03Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now
May 29TELA Bio, Inc. (NASDAQ:TELA) Soars 31% But It's A Story Of Risk Vs Reward
May 23Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Mar 24Many Still Looking Away From TELA Bio, Inc. (NASDAQ:TELA)
Mar 08TELA Bio (NASDAQ:TELA) Has Debt But No Earnings; Should You Worry?
Oct 07Getting In Cheap On TELA Bio, Inc. (NASDAQ:TELA) Might Be Difficult
Jul 31TELA Bio: Tailwinds In Hernia Repair Market And Promising Clinical Data To Drive Accelerating Adoption
Oct 02Tela Bio prices $32M common stock offering
Aug 16Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?
May 12TELA Bio - Follow Up With Management
Jan 14Our First Look At TELA Bio
Nov 04TELA Bio Plugging Away
Oct 25TELA Bio (TELA) Investor Presentation - Slideshow
May 26Revenue & Expenses Breakdown
How TELA Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 69 | -42 | 83 | 9 |
| 30 Jun 24 | 65 | -42 | 81 | 10 |
| 31 Mar 24 | 63 | -40 | 79 | 10 |
| 31 Dec 23 | 58 | -47 | 75 | 10 |
| 30 Sep 23 | 53 | -44 | 68 | 10 |
| 30 Jun 23 | 49 | -44 | 65 | 9 |
| 31 Mar 23 | 45 | -45 | 61 | 9 |
| 31 Dec 22 | 41 | -44 | 57 | 9 |
| 30 Sep 22 | 38 | -43 | 54 | 8 |
| 30 Jun 22 | 35 | -40 | 50 | 7 |
| 31 Mar 22 | 32 | -36 | 45 | 7 |
| 31 Dec 21 | 29 | -33 | 42 | 7 |
| 30 Sep 21 | 27 | -32 | 39 | 6 |
| 30 Jun 21 | 24 | -32 | 38 | 6 |
| 31 Mar 21 | 20 | -30 | 34 | 5 |
| 31 Dec 20 | 18 | -29 | 32 | 4 |
| 30 Sep 20 | 17 | -28 | 31 | 4 |
| 30 Jun 20 | 16 | -27 | 28 | 3 |
| 31 Mar 20 | 16 | -29 | 27 | 3 |
| 31 Dec 19 | 15 | -30 | 24 | 4 |
| 30 Sep 19 | 13 | -32 | 22 | 4 |
| 30 Jun 19 | 11 | -30 | 21 | 5 |
| 31 Mar 19 | 10 | -28 | 20 | 5 |
| 31 Dec 18 | 8 | -30 | 19 | 4 |
| 31 Dec 17 | 4 | -27 | 14 | 6 |
Quality Earnings: TELA is currently unprofitable.
Growing Profit Margin: TELA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TELA is unprofitable, and losses have increased over the past 5 years at a rate of 10.1% per year.
Accelerating Growth: Unable to compare TELA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TELA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (17.9%).
Return on Equity
High ROE: TELA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 02:06 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
TELA Bio, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyle Rose | Canaccord Genuity |
| William Plovanic | Canaccord Genuity |
| Caitlin Cronin | Canaccord Genuity |